Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 18Melanoma 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Esophageal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 9Breast Neoplasms 8Head and Neck Neoplasms 6Esophageal Squamous Cell Carcinoma 6Rectal Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Recurrence 4Neoplasms 4Carcinoma, Renal Cell 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Radiation Pneumonitis 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oropharyngeal Neoplasms 2

Interventions

Oxaliplatin 32Fluorouracil 24Gemcitabine 23Leucovorin 19Docetaxel 19pembrolizumab 17Capecitabine 15Radiotherapy 14Irinotecan 13Cisplatin 11Bevacizumab 11Nivolumab 8130-nm albumin-bound paclitaxel 8Trastuzumab 7Erlotinib Hydrochloride 7Cyclophosphamide 7Albumin-Bound Paclitaxel 7Radiosurgery 6Paclitaxel 6Taxes 5S 1 (combination) 5Metformin 5Carboplatin 5Blood Specimen Collection 5Sunitinib 4Sorafenib 4Pemetrexed 4Esophagectomy 4Chemoradiotherapy 4Cetuximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma × Immunotherapy × Clear all
NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡